RxSight Announces Pricing of Public Offering of Common Stock

RxSight, maker of the RxSight Light Adjustable Lens system, announced it has priced its underwritten public offering.

RxSight expects to sell 4 million shares of its common stock at a price to the public of $12.50 per share. RxSight has granted the underwriter a 30-day option to purchase up to an additional 600,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are to be sold by RxSight, which expects to receive gross proceeds of approximately $50 million. The offering is expected to close on or about February 10, 2023.

RxSight intends to use the net proceeds from the offering for continued commercial and marketing expansion, funding of product development, research and clinical development, and for working capital and general corporate purposes.